Figures and Tables

From the following article:

Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes

Jill C. Milne, Philip D. Lambert, Simon Schenk, David P. Carney, Jesse J. Smith, David J. Gagne, Lei Jin, Olivier Boss, Robert B. Perni, Chi B. Vu, Jean E. Bemis, Roger Xie, Jeremy S. Disch, Pui Yee Ng, Joseph J. Nunes, Amy V. Lynch, Hongying Yang, Heidi Galonek, Kristine Israelian, Wendy Choy, Andre Iffland, Siva Lavu, Oliver Medvedik, David A. Sinclair, Jerrold M. Olefsky, Michael R. Jirousek, Peter J. Elliott & Christoph H. Westphal

Nature 450, 712-716(29 November 2007)

doi:10.1038/nature06261

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 1

Identification of potent SIRT1 activators unrelated to resveratrol.

Full size figure and legend (160K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 2

In vitro characterization of activators of human SIRT1.

Full size figure and legend (200K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 3

SIRT1 activators in mouse models of type 2 diabetes.

Full size figure and legend (221K)
Figure 4 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.com

Figure 4

SIRT1 activator SRT1720 in the Zucker fa/fa rat model.

Full size figure and legend (129K)
BACK TO ARTICLE